184 related articles for article (PubMed ID: 20424139)
21. Clinical relevance of the bile acid receptor TGR5 in metabolism.
van Nierop FS; Scheltema MJ; Eggink HM; Pols TW; Sonne DP; Knop FK; Soeters MR
Lancet Diabetes Endocrinol; 2017 Mar; 5(3):224-233. PubMed ID: 27639537
[TBL] [Abstract][Full Text] [Related]
22. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery.
Patriti A; Facchiano E; Sanna A; Gullà N; Donini A
Obes Surg; 2004; 14(6):840-8. PubMed ID: 15318993
[TBL] [Abstract][Full Text] [Related]
23. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.
Potthoff MJ; Potts A; He T; Duarte JA; Taussig R; Mangelsdorf DJ; Kliewer SA; Burgess SC
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G371-80. PubMed ID: 23257920
[TBL] [Abstract][Full Text] [Related]
24. The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance.
Yan X; Li P; Tang Z; Feng B
BMC Endocr Disord; 2017 Sep; 17(1):60. PubMed ID: 28946907
[TBL] [Abstract][Full Text] [Related]
25. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
26. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans.
Wu T; Bound MJ; Standfield SD; Gedulin B; Jones KL; Horowitz M; Rayner CK
Diabetes Obes Metab; 2013 May; 15(5):474-7. PubMed ID: 23181598
[TBL] [Abstract][Full Text] [Related]
27. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes.
Yang JI; Yoon JH; Myung SJ; Gwak GY; Kim W; Chung GE; Lee SH; Lee SM; Kim CY; Lee HS
Biochem Biophys Res Commun; 2007 Sep; 361(1):156-61. PubMed ID: 17659258
[TBL] [Abstract][Full Text] [Related]
28. Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway.
Yusta B; Matthews D; Flock GB; Ussher JR; Lavoie B; Mawe GM; Drucker DJ
Mol Metab; 2017 Jun; 6(6):503-511. PubMed ID: 28580281
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
30. Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice.
Briere DA; Ruan X; Cheng CC; Siesky AM; Fitch TE; Dominguez C; Sanfeliciano SG; Montero C; Suen CS; Xu Y; Coskun T; Michael MD
PLoS One; 2015; 10(8):e0136873. PubMed ID: 26312995
[TBL] [Abstract][Full Text] [Related]
31. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
Nauck MA; Holst JJ; Willms B; Schmiegel W
Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
D'Alessio DA; Vahl TP
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
34. A selective small molecule glucagon-like peptide-1 secretagogue acting via depolarization-coupled Ca(2+) influx.
Eiki J; Saeki K; Nagano N; Iino T; Yonemoto M; Takayenoki-Iino Y; Ito S; Nishimura T; Sato Y; Bamba M; Watanabe H; Sasaki K; Ohyama S; Kanatani A; Nagase T; Yada T
J Endocrinol; 2009 Jun; 201(3):361-7. PubMed ID: 19332449
[TBL] [Abstract][Full Text] [Related]
35. TGR5-mediated bile acid sensing controls glucose homeostasis.
Thomas C; Gioiello A; Noriega L; Strehle A; Oury J; Rizzo G; Macchiarulo A; Yamamoto H; Mataki C; Pruzanski M; Pellicciari R; Auwerx J; Schoonjans K
Cell Metab; 2009 Sep; 10(3):167-77. PubMed ID: 19723493
[TBL] [Abstract][Full Text] [Related]
36. Intestinal Bile Acid Composition Modulates Prohormone Convertase 1/3 (PC1/3) Expression and Consequent GLP-1 Production in Male Mice.
Morimoto K; Watanabe M; Sugizaki T; Irie J; Itoh H
Endocrinology; 2016 Mar; 157(3):1071-81. PubMed ID: 26789236
[TBL] [Abstract][Full Text] [Related]
37. Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids.
Kashihara H; Shimada M; Kurita N; Sato H; Yoshikawa K; Higashijima J; Chikakiyo M; Nishi M; Takasu C
J Gastroenterol Hepatol; 2015 Feb; 30(2):308-15. PubMed ID: 25088988
[TBL] [Abstract][Full Text] [Related]
38. Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways.
Burrin D; Stoll B; Moore D
J Anim Sci; 2013 May; 91(5):1991-2000. PubMed ID: 23729782
[TBL] [Abstract][Full Text] [Related]
39. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization.
Prawitt J; Caron S; Staels B
Trends Endocrinol Metab; 2014 May; 25(5):235-44. PubMed ID: 24731596
[TBL] [Abstract][Full Text] [Related]
40. Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance.
Lasalle M; Hoguet V; Hennuyer N; Leroux F; Piveteau C; Belloy L; Lestavel S; Vallez E; Dorchies E; Duplan I; Sevin E; Culot M; Gosselet F; Boulahjar R; Herledan A; Staels B; Deprez B; Tailleux A; Charton J
J Med Chem; 2017 May; 60(10):4185-4211. PubMed ID: 28414465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
